Gliclazide Use in Acute Kidney Injury

Introduction to Gliclazide Risks

The American College of Clinical Nutrition recommends avoiding gliclazide in patients with acute kidney injury due to the substantially elevated risk of severe and prolonged hypoglycemia caused by impaired drug clearance and reduced renal gluconeogenesis 1, 2, 3

Acute kidney injury creates two critical problems that dramatically increase hypoglycemia risk with sulfonylureas like gliclazide, including decreased drug clearance and impaired renal gluconeogenesis 4
Patients with substantial decreases in kidney function have a 5-fold increase in the frequency of severe hypoglycemia when using glucose-lowering agents like sulfonylureas 4

The American Diabetes Association recommends maintaining serum glucose between 140-180 mg/dL in hospitalized patients with AKI (Grade A recommendation, 96% consensus) 1, 2, 3
The American College of Clinical Nutrition recommends avoiding tight glucose control (80-110 mg/dL) in AKI patients (Grade A recommendation, 100% consensus) 1, 2, 3

The European Association for the Study of Diabetes recommends using insulin as the mainstay of treatment for glucose control in patients with AKI, particularly those requiring dialysis 4
If an oral agent is necessary, the American College of Clinical Nutrition recommends glipizide as the preferred sulfonylurea because it lacks active metabolites that accumulate in kidney dysfunction 4, 6

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend completely avoiding chlorpropamide, tolazamide, and tolbutamide in any degree of kidney impairment due to their prolonged half-lives and extremely high hypoglycemia risk 4, 6
The American College of Clinical Nutrition recommends recognizing high-risk clinical scenarios, such as acute illness or sepsis, surgery or prolonged fasting, administration of contrast agents, and use of NSAIDs or other nephrotoxic medications, and temporarily discontinuing or substantially reducing gliclazide doses during these scenarios 4, 5, 6